ALDH5A1
ENSG00000112294
Target class
Enzyme
Chromosome
6
Approved drugs
3
Clinical candidates (approved and in development)
3
- Approved drugs
- 3
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- ALDH5A1
- Gene name
- Aldehyde dehydrogenase 5 family member A1
- Gene symbol
- ALDH5A1
- Protein name
- Succinate-semialdehyde dehydrogenase, mitochondrial (EC 1.2.1.24) (Aldehyde dehydrogenase family 5 member A1) (NAD(+)-dependent succinic semialdehyde dehydrogenase)
- SSADH
- SSDH
- Gene biotype
- Protein coding
- Gene family
- Aldehyde dehydrogenases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 46.73
- Tissue specificity (Gini)
- 0.436
- Tissue specificity (tau)
- 0.689
- KEGG gene identifiers
- hsa:7915
- Reactome pathways
- R-HSA-916853
- Protein interaction confidence
- 0.84955
- Protein interaction partners
- 20
- End position
- 24537207
- Start position
- 24494798
- Chromosome
- 6
- Strand
- Forward
- Mitochondrion.
- Mitochondria
- Tissue specificity (tau)
- 0.689489
- Expression inequality (Gini)
- 0.436309
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 46.73
- Brain - Nucleus accumbens (basal ganglia)
- 45.91
- Brain - Anterior cingulate cortex (BA24)
- 42.85
- Brain - Caudate (basal ganglia)
- 39.44
- Brain - Cerebellar Hemisphere
- 39.36
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)46.73
- Brain - Nucleus accumbens (basal ganglia)45.91
- Brain - Anterior cingulate cortex (BA24)42.85
- Brain - Caudate (basal ganglia)39.44
- Brain - Cerebellar Hemisphere39.36
- Brain - Cortex38.25
- Brain - Hypothalamus37.29
- Brain - Cerebellum34.87
- Liver32.88
- Brain - Amygdala32.76
- Brain - Putamen (basal ganglia)27.97
- Brain - Substantia nigra25.12
- Brain - Hippocampus23.49
- Brain - Spinal cord (cervical c-1)20.38
- Cells - EBV-transformed lymphocytes18.05
- Vagina17.29
- Thyroid15.54
- Muscle - Skeletal15.05
- Nerve - Tibial13.59
- Pituitary12.3
- Ovary12.06
- Skin - Not Sun Exposed (Suprapubic)11.28
- Skin - Sun Exposed (Lower leg)11.08
- Testis10.68
- Prostate10.05
And 29 more, listed on the interactive page.
- GO:0006540
- GO:0007417
- GO:0009450
- GO:0005739
- GO:0005759
- GO:0004777
- GO:0042802
Related records
Trials (326)
- A Comparison of Fluoxetine and Divalproex for the Treatment of Intermittent Explosive Disorder
- A Comparison of Olanzapine in Combination With a Mood Stabilizer vs Mood Stabilizer Alone, in Mixed Bipolar Patients
- A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
- A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR
- A Cross-sectional Study to Investigate the Effect of Topiramate on Bone and Mineral Metabolism in Female Participants With Epilepsy
- A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures
- A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder
- A Drug Interaction Study of Valproic Acid and Single-dose Paliperidone Extended-Release (ER) in Healthy Men
- A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights
- A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
- A Phase II Study of Epigenetic Therapy to Overcome Chemotherapy Resistance in Refractory Solid Tumors
- A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
- A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.
- A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents
- A Study for Treatment of Partial Seizures in Children
- A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets
- A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG
- A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)
- A Study of the Effectiveness and Safety of Topiramate Compared With a Standard Therapy in Patients Newly Diagnosed With Epilepsy
- A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
Drugs (4)
- Divalproex sodium Succinate semialdehyde dehydrogenase inhibitor
- Magnesium valproate Succinate semialdehyde dehydrogenase inhibitor
- Valproate sodium Succinate semialdehyde dehydrogenase inhibitor
- Valproic acid Succinate semialdehyde dehydrogenase inhibitor